

Clinical Policy: Inhaled Agents for Asthma and COPD

Reference Number: CP.CPA.350

Effective Date: 03.01.21

Last Review Date: 02.26

Line of Business: Commercial

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

The following are inhaled agents for asthma and/or chronic obstructive pulmonary disease (COPD) requiring prior authorization:

- Short acting beta-2 agonist (SABA): albuterol (ProAir[®] Digihaler[®])
- Inhaled corticosteroid (ICS): ciclesonide (Alvesco[®]), fluticasone (ArmonAir[®] Digihaler[™]), mometasone (Asmanex[®] HFA, Asmanex[®] Twisthaler[®])
- Long acting beta-2 agonist (LABA): arformoterol (Brovana[®]), formoterol (Perforomist)
- Long acting muscarinic antagonist (LAMA): aclidinium bromide (Tudorza[®] Pressair[®]), revefenacin (Yupelri[®])
- Combination ICS/LABA: budesonide/formoterol (Symbicort^{®*}, Symbicort Aerosphere[®]), fluticasone/salmeterol (Advair Diskus^{®*}, Advair HFA^{®*}, AirDuo[®] Digihaler[™], AirDuo[®] RespiClick[®]), mometasone/formoterol (Dulera[®])
- Combination LABA/LAMA: aclidinium/formoterol (Duaklir[®] Pressair[®]), glycopyrrolate/formoterol (Bevespi Aerosphere[™])
- Phosphodiesterase 3 (PDE3) inhibitor and phosphodiesterase 4 (PDE4) inhibitor: ensifentrine (Ohtuvayre[™])

**Generic agents do not require prior authorization.*

FDA Approved Indication(s)

ProAir Digihaler is indicated for the:

- Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease
- Prevention of exercise-induced bronchospasm (EIB) in patients 4 years of age and older

The other inhaled agents are indicated as follows:

Drug Name	Asthma	COPD
ICS		
Alvesco	X (Age ≥ 12 years)	
ArmonAir Digihaler	X (Age ≥ 4 years)	
Asmanex HFA	X (Age ≥ 5 years)	
Asmanex Twisthaler	X (Age ≥ 4 years)	
LABA		
Brovana		X
Perforomist		X

Drug Name	Asthma	COPD
LAMA		
Tudorza Pressair		X
Yupelri		X
ICS/LABA		
Advair Diskus	X (Age ≥ 4 years)	X
Advair HFA	X (Age ≥ 12 years)	
AirDuo Digihaler	X (Age ≥ 12 years)	
AirDuo RespiClick	X (Age ≥ 12 years)	
Dulera	X (Age ≥ 5 years)	
Symbicort	X (Age ≥ 6 years)	X
Symbicort Aerosphere		X
LABA/LAMA		
Bevespi Aerosphere		X
Duaklir Pressair		X
PDE3/PDE4 Inhibitor		
Ohtuvayre		X

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that inhaled agents for asthma and COPD are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. All Requests (must meet all):

1. Diagnosis of asthma or COPD as FDA-approved for the requested agent (*see FDA Approved Indications section*);
2. Age is one of the following (a or b):
 - a. Asthma: Appropriate per the prescribing information for the requested agent (*see FDA Approved Indications section*);
 - b. COPD: ≥ 18 years;
3. Failure of the following formulary agent(s) at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated:

Requested Agent	Required Step Through Agent(s)
ProAir Digihaler	Two generic albuterol sulfate HFA products, each from a different manufacturer
<u>All other ICS</u> : Alvesco, Armonair Digihaler, Asmanex HFA, Asmanex Twisthaler	Qvar [®] RediHaler [™] AND Pulmicort Flexhaler [™] AND Arnuity [®] Ellipta [®] AND fluticasone propionate HFA (Flovent [®] HFA authorized generic)
<u>LABA</u> : Brand Brovana	Medical justification supports inability to use generic arformoterol (generic Brovana), Serevent [®] Diskus [®]

Requested Agent	Required Step Through Agent(s)
	<i>AND</i> Striverdi [®] Respimat [®] , unless documentation supports inability to use inhaler devices
<u>LABA</u> : Brand Perforomist	Medical justification supports inability to use generic formoterol (generic Perforomist), Serevent [®] Diskus [®] <i>AND</i> Striverdi [®] Respimat [®] , unless documentation supports inability to use inhaler devices
<u>LAMA</u> : Tudorza Pressair, Yupelri	Incruse [®] Ellipta [®] <i>AND</i> Spiriva [®] Handihaler [®] /Respimat [®] , unless request is for a nebulized LAMA and documentation supports inability to use inhaler devices
Brand Advair Diskus	Medical justification supports inability to use generic fluticasone/salmeterol products (generic Advair Diskus, Wixela [™] Inhub [™]) (e.g., contraindications to excipients)
Brand Advair HFA	Medical justification supports inability to use fluticasone-salmeterol HFA (Advair HFA authorized generic) (e.g., contraindications to excipients)
Brand Symbicort, Symbicort Aerosphere	Medical justification supports inability to use generic Symbicort (e.g., contraindications to excipients)
<u>All other ICS/LABA – for California Exchange Plans ONLY</u> : AirDuo Digihaler, AirDuo RespiClick	fluticasone-salmeterol HFA (Advair HFA authorized generic) <i>AND</i> Breo Ellipta [®] /fluticasone furoate-vilanterol (Breo Ellipta authorized generic) <i>AND</i> budesonide/formoterol (generic Symbicort) <i>AND</i> fluticasone/salmeterol (generic Advair Diskus or Wixela Inhub) <i>AND</i> Dulera
<u>All other ICS/LABA – for all other Commercial formularies</u> : AirDuo Digihaler, AirDuo RespiClick, Dulera	fluticasone-salmeterol HFA (Advair HFA authorized generic) <i>AND</i> Breo Ellipta [®] /fluticasone furoate-vilanterol (Breo Ellipta authorized generic) <i>AND</i> budesonide/formoterol (generic Symbicort) <i>AND</i> fluticasone/salmeterol (generic Advair Diskus or Wixela Inhub)
<u>LABA/LAMA</u> : Bevespi Aerosphere, Duaklir Pressair	Stiolto [®] Respimat [®] <i>AND</i> Anoro [®] Ellipta [®]
Ohtuvayre	<ul style="list-style-type: none"> • Anoro Ellipta <i>OR</i> Stiolto Respimat <i>OR</i> one LABA (e.g., Serevent Diskus) in combination with one LAMA (e.g., Incruse Ellipta) <p><i>AND</i></p> <ul style="list-style-type: none"> • For members with blood eosinophil count ≥ 100 cells/mcL: Breztri Aerosphere[™] <i>OR</i> Trelegy[™] Ellipta[®] <p><i>Note: Prior failure of triple therapy (ICS/LABA/LAMA) satisfies the requirement for failure of dual therapy (LABA/LAMA).</i></p>

4. For requests for an agent with a digital component (e.g., Digihaler products): Medical justification supports necessity of the digital component (i.e., rationale why inhaler usage cannot be tracked manually);
5. For requests for Ohtuvayre, both of the following (a and b):
 - a. Member has moderate-to-severe COPD as evidenced by one of the following (i or ii):
 - i. Pre- and post-albuterol forced expiratory volume (FEV₁)/forced vital capacity (FVC) ratio of < 0.70;
 - ii. Post-albuterol FEV₁ ≥ 30 % and ≤ 70% of predicted normal;
 - b. Ohtuvayre is not prescribed in combination with Daliresp[®];
6. Request does not exceed one of the following (a or b):
 - a. The health plan quantity limit;
 - b. The FDA-approved maximum dose for the relevant indication (see *Section V*).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

II. Continued Therapy

A. All Requests in Section I (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. If request is for a dose increase, request does not exceed one of the following (a or b):
 - a. The health plan quantity limit;
 - b. The FDA-approved maximum dose for the relevant indication (see *Section V*).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

COPD: chronic obstructive pulmonary disease	GINA: Global Initiative for Asthma
EIB: exercise-induced bronchospasm	GOLD: Global Initiative for Chronic Obstructive Lung Disease
FDA: Food and Drug Administration	LABA: long acting beta-2 agonist
FEV ₁ : forced expiratory volume	LAMA: long acting muscarinic antagonist
FVC: forced vital capacity	PDE: phosphodiesterase
ICS: inhaled corticosteroid	SABA: short acting beta-2 agonist

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
fluticasone-salmeterol HFA (Advair HFA authorized generic)	Asthma: 2 inhalations BID (starting dosage is based on asthma severity)	Asthma: 2 inhalations of 230/21 mcg BID
albuterol (Proventil HFA [®] , Ventolin HFA [®])	<i>Metered-dose inhaler (MDI):</i> 2 puffs every 4 to 6 hours as needed <i>Nebulization solution:</i> 2.5 mg via oral inhalation every 6 to 8 hours as needed	<i>MDI:</i> 12 puffs/day <i>Nebulization solution:</i> 4 doses/day or 10 mg/day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
		Higher maximum dosages for inhalation products have been recommended in National Asthma Education and Prevention Program guidelines for acute exacerbations of asthma.
Anoro Ellipta (umeclidinium/vilanterol)	COPD: 1 inhalation by mouth QD	COPD: 1 inhalation/day
Arnuity Ellipta (fluticasone furoate)	Asthma: ≥ 12 years: 100-200 mcg inhaled QD 5-11 years: 50 mcg inhaled QD	Asthma: ≥ 12 years: 200 mcg/day 5-11 years: 50 mcg/day
Breo Ellipta (fluticasone/vilanterol)	Asthma: Age ≥ 18 years: 1 inhalation of 100/25 or 200/25 mcg QD Age 12-17 years: 1 inhalation of 100/25 mcg QD Age 5-11 years: 1 inhalation of 50/25 mcg QD COPD: 1 inhalation of 100/25 mcg QD	Asthma: 200/25 mcg/day COPD: 100/25 mcg/day
Breztri Aerosphere	COPD: 2 inhalations by mouth BID	4 inhalations/day
budesonide/formoterol (Symbicort)	Asthma: 2 inhalations BID COPD: 2 inhalations (160/4.5 mcg) BID	Asthma/COPD: 160/4.5 mcg BID
fluticasone (Flovent HFA)	Asthma: 1 inhalation BID	Asthma: 1,760 mcg/day
fluticasone/salmeterol (Advair Diskus, Wixela Inhub)	Asthma: 1 inhalation BID (starting dosage is based on asthma severity) COPD: 1 inhalation of 250/50 mcg BID	Asthma: 500/50 mcg BID COPD: 250/50 mcg BID
Incruse Ellipta (umeclidinium)	COPD: 1 inhalation (62.5 mcg) QD	COPD: 62.5 mcg/day
Pulmicort Flexhaler (budesonide)	Asthma: Starting dose of 180-360 mcg inhaled BID	Asthma: 720 mcg BID

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Qvar RediHaler (beclomethasone)	Asthma: ≥ 12 years: 40 mcg, 80 mcg, 160 mcg, or 320 mcg inhaled BID 4-11 years: 40 mcg or 80 mcg inhaled BID	Asthma: ≥ 12 years: 640 mcg/day 4-11 years: 160 mcg/day
Serevent (salmeterol)	Asthma/COPD: 1 inhalation (50 mcg) BID	Asthma/COPD: 100 mcg/day
Spiriva Handihaler (tiotropium bromide monohydrate)	COPD: 2 inhalations (18 mcg) QD	COPD: 18 mcg/day
Spiriva Respimat (tiotropium bromide monohydrate)	Asthma: 2 inhalations (1.25 mcg) QD COPD: 2 inhalations (2.5 mcg) QD	Asthma: 2.5 mcg/day COPD: 5 mcg/day
Stiolto Respimat (tiotropium/olodaterol)	COPD: 2 inhalations QD at the same time of day	COPD: 2 inhalations/day
Striverdi Respimat (olodaterol)	COPD: 2 inhalations QD	COPD: 5 mcg/day
Trelegy Ellipta (fluticasone/umeclidinium/vilanterol)	Asthma: 1 inhalation (100/62.5/26 mcg or 200/62.5/26 mcg) by mouth QD COPD: 1 inhalation (100/62.5/26 mcg) by mouth QD	Asthma: 200/62.5/26 mcg/day COPD: 100/62.5/26 mcg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - All agents: hypersensitivity to any component of the requested agent or the following as additionally specified:
 - Advair Diskus, AirDuo Digihaler/RespiClick, ArmonAir Digihaler, Asmanex Twisthaler, Tudorza Pressair: milk proteins
 - Brovana: racemic formoterol
 - Advair HFA/Diskus, AirDuo Digihaler/RespiClick, Alvesco, ArmonAir Digihaler, Asmanex HFA/Twisthaler, Dulera: primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures
 - Bevespi Aerosphere, Brovana, Duaklir Pressair, Perforomist: use of a LABA without an ICS in patients with asthma
- Boxed warning(s): none reported

Appendix D: General Information

- Although inhaler devices with a digital component may offer increased convenience with tracking of inhaler usage, there is currently no evidence that this leads to improved clinical outcomes, including safety and effectiveness.

- Per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD guidelines, combination therapy (LAMA + LABA or ICS + LAMA + LABA) is recommended for Group B and E patients (i.e., those who are very symptomatic or have had an exacerbation in the last year). Selection of which combination to use depends on the individual patient:
 - For those with more severe symptoms, LAMA + LABA may be used.
 - For those who are inadequately controlled by dual therapy or with blood eosinophil counts at least 300 cells/uL, triple therapy with ICS + LAMA + LABA may be used.
 - As of the 2023 guideline update, use of LABA + ICS in COPD is no longer encouraged. If there is an indication for an ICS, then LABA + LAMA + ICS has been shown to be superior to LABA + ICS and is therefore the preferred choice.
 - Ohtuvayre may be considered in patients experiencing dyspnea despite LABA + LAMA therapy. For patients experiencing exacerbations despite LABA + LAMA therapy, triple therapy with ICS + LAMA + LABA is instead recommended. This is because while Ohtuvayre improves lung function, its effect on exacerbations has not been evaluated in patients at increased exacerbation risk; conversely, ICS + LAMA + LABA has been shown to reduce exacerbations and may also confer mortality benefit.
- Historical management of asthma has involved an as-needed short-acting beta agonist for reliever therapy, with stepwise approach to add on controller maintenance therapies such as inhaled corticosteroids and long-acting beta agonists. In 2019, the Global Initiative for Asthma (GINA) guidelines for asthma management and prevention began recommending that inhaled corticosteroids be initiated as soon as possible after diagnosis of asthma, including use as reliever therapy (to be administered as-needed alongside a short-acting beta agonist). The National Asthma Education and Prevention Program from the National Heart, Lung, and Blood Institute followed suit with their recommendations in 2020.
- Alvesco: Use in pediatric patients < 12 years of age: Two identically designed randomized, double-blind, parallel, placebo-controlled clinical trials of 12-weeks treatment duration were conducted in 1,018 patients aged 4 to 11 years with asthma but efficacy was not established. In addition, one randomized, double-blind, parallel, placebo-controlled clinical trial did not establish efficacy in 992 patients aged 2 to 6 years with asthma.

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Advair Diskus	Asthma	1 inhalation BID (starting dosage is based on asthma severity)	500/50 mcg BID
	COPD	1 inhalation of 250/50 mcg BID	250/50 mcg BID
Advair HFA	Asthma	2 inhalations BID (starting dosage is based on asthma severity)	2 inhalations of 230/21 mcg BID
AirDuo Digihaler	Asthma	1 inhalation BID (starting dosage is based on asthma severity)	232/14 mcg BID
AirDuo RespiClick	Asthma	1 inhalation BID (starting dosage is based on asthma severity)	232/14 mcg BID

Drug Name	Indication	Dosing Regimen	Maximum Dose
Alvesco	Asthma	Starting dose for patients who received bronchodilators alone: 80 mcg inhaled BID	320 mcg/day
		Starting dose for patients who received inhaled corticosteroids: 80 mcg inhaled BID	640 mcg/day
		Starting dose for patients who received oral corticosteroids: 320 mcg inhaled BID	640 mcg/day
ArmonAir Digihaler	Asthma	1 inhalation BID (starting dosage is based on asthma severity)	232 mcg BID
Asmanex HFA	Asthma	2 inhalations BID (starting dosage is based on age and asthma severity)	800 mcg/day
Asmanex Twisthaler	Asthma	Dose varies based on previous therapy and age: 1 inhalation QD-BID	880 mcg/day
Bevespi Aerosphere	COPD	2 inhalations BID	4 inhalations/day
Brovana	COPD	One 15 mcg/2 mL vial inhaled via nebulizer every 12 hours	30 mcg/day
Duaklir Pressair	COPD	One inhalation by mouth BID	2 inhalations/day
Dulera	Asthma	Age 5 to 11 years: 2 inhalations of 50/5 mcg BID	200/5 mcg/day
		Age ≥ 12 years: 2 inhalations of 100/5 mcg or 200/5 mcg BID (starting dosage is based on asthma severity)	800/20 mcg/day
Ohtuvayre	COPD	3 mg (one ampule) inhaled via nebulizer BID	6 mg/day
Perforomist	COPD	One 20 mcg/2 mL vial inhaled via nebulizer every 12 hours	40 mcg/day
ProAir Digihaler	Treatment or prevention of bronchospasm	2 inhalations every 4 to 6 hours	12 inhalations/day
	Prevention of EIB	2 inhalations 15 to 30 minutes before exercise	2 inhalations before exercise
Symbicort	Asthma	2 inhalations BID (starting dosage is based on asthma severity)	320/9 mcg BID
	COPD	2 inhalations (160/4.5 mcg) BID	320/9 mcg BID
Symbicort Aerosphere	COPD	2 inhalations (160/4.8 mcg) BID	320/9.6 mcg BID

Drug Name	Indication	Dosing Regimen	Maximum Dose
Tudorza Pressair	COPD	1 inhalation (400 mcg) BID	800 mcg/day
Yupelri	COPD	One 175 mcg mcg vial inhaled via nebulizer QD	175 mcg/day

VI. Product Availability

Drug Name	Availability
Advair Diskus	Inhalation powder containing fluticasone/salmeterol: 100/50 mcg, 250/50 mcg, 500/50 mcg
Advair HFA	Inhalation aerosol containing fluticasone/salmeterol: 45/21 mcg, 115/21 mcg, 230/21 mcg
AirDuo Digihaler	Inhalation powder: In each actuation: 55/14 mcg contains 55 mcg of fluticasone propionate and 14 mcg of salmeterol; 113/14 mcg contains 113 mcg of fluticasone propionate and 14 mcg of salmeterol; 232/14 mcg contains 232 mcg of fluticasone propionate and 14 mcg of salmeterol. AirDuo Digihaler contains a built-in electronic module
AirDuo RespiClick	Inhalation powder: In each actuation: 55 mcg/14 mcg contains 55 mcg of fluticasone propionate and 14 mcg of salmeterol; 113 mcg/14 mcg contains 113 mcg of fluticasone propionate and 14 mcg of salmeterol; 232 mcg/14 mcg contains 232 mcg of fluticasone propionate and 14 mcg of salmeterol
Alvesco	Inhalation aerosol: 80 mcg/actuation, 160 mcg/actuation
ArmonAir Digihaler	Inhalation powder containing 55 mcg, 113 mcg, or 232 mcg of fluticasone propionate per actuation. ArmonAir Digihaler contains a built-in electronic module
Asmanex HFA	Inhalation aerosol containing 50 mcg, 100 mcg, or 200 mcg of mometasone furoate per actuation
Asmanex Twisthaler	Inhalation device: 110 mcg (delivers 100 mcg/actuation), 220 mcg (delivers 200 mcg/actuation)
Bevespi Aerosphere	Inhalation aerosol: pressurized metered dose inhaler containing a combination of glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) per inhalation; two inhalations equal one dose
Brovana	Inhalation solution (unit-dose vial for nebulization): 15 mcg/2 mL
Duaklir Pressair	Inhalation powder: 30 and 60 metered dose dry powder inhaler metering 400 mcg aclidinium bromide and 12 mcg formoterol fumarate per actuation
Dulera	Inhalation aerosol containing mometasone/formoterol: 50/5 mcg, 100/5 mcg, 200/5 mcg per actuation
Ohtuvayre	Inhalation suspension in unit-dose ampule: 3 mg/2.5 mL
Perforomist	Inhalation solution (unit dose vial for nebulization): 20 mcg/2 mL solution
ProAir Digihaler	Inhalation powder: dry powder inhaler 108 mcg of albuterol sulfate (equivalent to 90 mcg of albuterol base) from the mouthpiece per actuation. The inhaler is supplied for 200 inhalation doses. ProAir Digihaler includes a built-in electronic module

Drug Name	Availability
Symbicort	Metered-dose inhaler: budesonide (80 or 160 mcg) and formoterol (4.5 mcg) as an inhalation aerosol
Symbicort Aerosphere	Metered-dose inhaler: budesonide (160 mcg) and formoterol (4.8 mcg) as an inhalation aerosol
Tudorza Pressair	Inhalation powder in a multi-dose dry powder inhaler: 400 mcg/actuation
Yupelri	Inhalation solution (unit-dose vial for nebulization): 175 mcg/3 mL

VII. References

SABA

1. ProAir Digihaler Prescribing Information. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; September 2020. Available at: https://www.proair.com/globalassets/proair/hfa/proair_digihaler_pil.pdf. Accessed October 27, 2025.

ICS

2. Alvesco Prescribing Information. Marlborough, MA: Sunovion Pharmaceuticals Inc.; February 2023. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021658s011lbl.pdf. Accessed October 27, 2025.
3. ArmonAir Digihaler Prescribing Information. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; April 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208798s013lbl.pdf. Accessed October 27, 2025.
4. Asmanex HFA Prescribing Information. Jersey City, NJ: Organon & Co.; June 2025. Available at: https://www.merck.com/product/usa/pi_circulars/a/asmanex_hfa/asmanex_hfa_pi.pdf. Accessed October 27, 2025.
5. Asmanex Twisthaler Prescribing Information. Jersey City, NJ: Organon & Co.; June 2021. Available at: https://www.merck.com/product/usa/pi_circulars/a/asmanex/asmanex_pi.pdf. Accessed October 27, 2025.

LABA

6. Brovana Prescribing Information. Marlborough, MA: Sunovion Pharmaceuticals Inc.; May 2019. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021912s032lbl.pdf. Accessed October 27, 2025.
7. Perforomist Prescribing Information. Morgantown, WV: Mylan Specialty L.P.; May 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf. Accessed October 27, 2025.

LAMA

8. Tudorza Pressair Prescribing Information. Wilmington, DE: AstraZeneca; August 2022. Available at: <https://www.tudorza.com/pdf/tudorza-pressair-prescribing-information.pdf>. Accessed October 27, 2025.
9. Yupelri Prescribing Information. Morgantown, WV: Mylan Specialty L.P.; May 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210598s003lbl.pdf. Accessed October 27, 2025.

ICS/LABA

10. Advair Diskus Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; June 2023. Available at https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Advair_Diskus/pdf/ADVAIR-DISKUS-PI-PIL-IFU.PDF. Accessed October 27, 2025.
11. Advair HFA Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; May 2024. Available at https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Advair_HFA/pdf/ADVAIR-HFA-PI-PIL-IFU.PDF. Accessed October 27, 2025.
12. AirDuo Digihaler Prescribing Information. Frazer, PA: Teva Respiratory, LLC; July 2021. Available at: https://www.digihaler.com/globalassets/airduo_digihaler/airduo_digihaler_pi.pdf. Accessed October 28, 2024.
13. AirDuo RespiClick Prescribing Information. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; July 2021. Available at: <https://www.myairduo.com/globalassets/myairduo/pdf/pi.pdf>. Accessed October 27, 2025.
14. Dulera Prescribing Information. Jersey City, NJ: Organon & Co.; June 2025. Available at https://www.organon.com/product/usa/pi_circulars/d/dulera/dulera_pi.pdf. Accessed October 27, 2025.
15. Symbicort Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals; July 2019. Available at: <https://www.symbicorttouchpoints.com/>. Accessed October 27, 2025.
16. Symbicort Aerosphere Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals; April 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216579s000lbl.pdf. Accessed October 27, 2025.

LABA/LAMA

17. Bevespi Aerosphere Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals; March 2023. Available at: <https://www.bevespi.com/>. Accessed October 27, 2025.
18. Duaklir Pressair Prescribing Information. Morrisville, NC: Circassia Pharmaceuticals Inc.; March 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210595lbl.pdf. Accessed October 27, 2025.

PDE3/PDE4 Inhibitor

19. Ohtuvayre Prescribing Information. Raleigh, NC: Verona Pharma, Inc; July 2025. Available at: www.ohtuvayrehcp.com. Accessed October 27, 2025.
20. Anzueto A et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: Randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). *Am J Respir Crit Care Med.* 2023; 208(4): 406-416. doi:10.1164/rccm.202306-0944OC.

Guidelines

21. National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program. Published August 28, 2007. Available from: <https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma>. Accessed November 12, 2025.

22. Cloutler MM, Dixon AE, Krishnan JA, et al. Managing asthma in adolescents and adults 2020: asthma guideline update from the National Asthma Education and Prevention Program. JAMA. 2020; 324: 2301-2317.
23. Global Initiative for Asthma. Global strategy for asthma management and prevention (2025 report). Available from: www.ginasthma.org. Accessed November 12, 2025.
24. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2026 report). Available at: <http://www.goldcopd.org>. Accessed November 12, 2025.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J7601	Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2022 annual review: no significant changes; references reviewed and updated.	09.21.21	02.22
Per May SDC and prior clinical guidance, for Brovana and Perforomist added requirement for use of their respective generics, in addition to previously required Serevent Diskus and Striverdi Respimat.	05.20.22	
Template changes applied to other diagnoses/indications and continued therapy section.	09.28.22	
1Q 2023 annual review: no significant changes; updated Appendix D with updated 2023 GOLD guideline recommendations; references reviewed and updated.	01.11.23	02.23
RT4: added newly approved dosage form Symbicort Aerosphere to policy with redirection to generic Symbicort per SDC and prior clinical guidance; updated dosing for Breo Ellipta in Appendix B per prescribing information for pediatric extension down to 5 years of age and older. Corrected maximum dose for Bevespi Aerosphere from 2 inhalations/day to 4 inhalations/day per dosing regimen (2 inhalations BID).	05.26.23	
Per September SDC and prior clinical guidance, revised redirection from brand Flovent HFA/Flovent Diskus to instead redirect to fluticasone propionate HFA (Flovent HFA authorized generic), added Flovent HFA and Advair HFA to policy requiring redirection to authorized generic, revised redirection from brand Advair HFA to	09.21.23	12.23

Reviews, Revisions, and Approvals	Date	P&T Approval Date
instead redirect to fluticasone-salmeterol HFA (Advair HFA authorized generic), revised redirection to Breo Ellipta to allow either brand or authorized generic.		
1Q 2024 annual review: no significant changes; references reviewed and updated.	10.09.23	02.24
Per March SDC, for “All other ICS/LABA” created separate row for California Exchange Plans requiring an additional redirection to Dulera.	03.12.24	05.24
RT4: added newly approved agent Ohtuvayre with redirections per SDC.	07.03.24	11.24
HCPCS code added [J7601].	11.06.24	
1Q 2025 annual review: no significant changes; updated Appendix D with latest GOLD guideline recommendations on Ohtuvayre; references reviewed and updated.	11.14.24	02.25
Removed Arcapta Neohaler from criteria as it is no longer commercially available.	08.04.25	
1Q 2026 annual review: no significant changes; removed the following off-market products: Flovent Diskus, Flovent HFA, Lonhala Magnair, Seebri Neohaler, Utibron Neohaler; references reviewed and updated.	11.12.25	02.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.